BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 9629877)

  • 1. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.
    Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ
    Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting.
    Spitzer TR; Grunberg SM; Dicato MA
    Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal selection of antiemetics in children receiving cancer chemotherapy.
    Roila F; Aapro M; Stewart A
    Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic drugs.
    Cranwell-Bruce L
    Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
    [No Abstract]   [Full Text] [Related]  

  • 5. [Management of nausea, vomiting and anorexia due to anticancer agents].
    Shimada K; Taguchi S
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):760-4. PubMed ID: 12852341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 7. Serotonin antagonists: treatment of chemotherapy-induced emesis.
    Barisano A; Mehl B; Bradbury K
    Mt Sinai J Med; 1992 Oct; 59(5):433-7. PubMed ID: 1435844
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
    Hartvig P
    J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
    [No Abstract]   [Full Text] [Related]  

  • 13. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticipatory nausea and vomiting.
    Aapro MS; Molassiotis A; Olver I
    Support Care Cancer; 2005 Feb; 13(2):117-21. PubMed ID: 15599779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in use of the 5-HT3 receptor antagonists.
    Walton SM
    Expert Opin Pharmacother; 2000 Jan; 1(2):207-23. PubMed ID: 11249543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus regarding multiple day and rescue antiemetic therapy.
    De Mulder PH; Roila F; Kris MG; Marty MM
    Support Care Cancer; 1998 May; 6(3):248-52. PubMed ID: 9629878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
    Antonarakis ES; Hain RD
    Arch Dis Child; 2004 Sep; 89(9):877-80. PubMed ID: 15321871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings.
    Hickok JT; Roscoe JA; Morrow GR; Stern RM; Yang B; Flynn PJ; Hynes HE; Kirshner JJ; Rosenbluth RJ
    Cancer; 1999 Jul; 86(1):64-71. PubMed ID: 10391565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
    Rizk AN; Hesketh PJ
    Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.